Sobering OS Data With Maintenance Niraparib in Recurrent Ovarian Cancer
Niraparib (Zejula) maintenance did not improve overall survival (OS) in patients with platinum-sensitive…
Browsing Tag
niraparib
Zai Lab to Present Two New Phase 3 Analyses for Niraparib in Ovarian Cancer at the…
<!-- Name:DistributionId Value:8754743 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
OS Benefit Eludes Second-Line Niraparib Maintenance in Ovarian Cancer
For women with platinum-sensitive recurrent ovarian cancer, maintenance therapy using an…
Zai Lab Presents Interim Overall Survival Data for ZEJULA® (niraparib) from the NORA…
- Median overall survival (mOS) was numerically longer for patients receiving ZEJULA regardless of biomarker status, at 46.3 months compared to 43.4 months in the placebo group- No new…
Zai Lab to Present Analysis of the Impact of Timing for ZEJULA® (niraparib)…
SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global…